Fifth Third Wealth Advisors LLC Acquires 278 Shares of Edwards Lifesciences Co. (NYSE:EW)

Fifth Third Wealth Advisors LLC grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,584 shares of the medical research company’s stock after buying an additional 278 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $413,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter worth $30,000. Prospera Private Wealth LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth about $32,000. Avior Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares in the last quarter. Peoples Bank KS bought a new stake in Edwards Lifesciences in the 3rd quarter valued at about $40,000. Finally, JFS Wealth Advisors LLC increased its position in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research reports. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective for the company. in a research note on Thursday. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Finally, Citigroup raised their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $69.87 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm’s 50-day simple moving average is $71.91 and its two-hundred day simple moving average is $71.61. The firm has a market cap of $41.21 billion, a price-to-earnings ratio of 10.08, a P/E/G ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the business earned $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,000 shares of company stock worth $2,195,180. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.